Get started
Author

Alessandro Cappetta

Observed names: A Cappetta, A. CAPPETTA, A. Cappetta, ALESSANDRO CAPPETTA, Cappetta, Alessandro
ORCID: 0000-0002-2147-2790
Observed ORCID: 0000-0002-2147-2790
OpenAlex ID: A5088550918
Neoplastic Meningitis from Solid Tumors: New Diagnostic and Therapeutic Approaches
2011 · Giuseppe Lombardi, Fable Zustovich, et al. · The Oncologist · 43
Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies
2011 · Alessandro Cappetta, Sara Lonardi, et al. · Critical Reviews in Oncology/Hematology · 33
Hepatoid Adenocarcinoma of the Colon: What Should We Target?
2011 · Alessandro Cappetta, Francesca Bergamo, et al. · Pathology & Oncology Research · 30
Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study
2023 · Floriana Nappo, Lorenzo Fornaro, et al. · Journal of Cancer Research and Clinical Oncology · 29
Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma
2022 · Margherita Rimini, Teresa Macarulla, et al. · European Journal of Cancer · 25
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG
2020 · Melissa Bersanelli, Diana Giannarelli, et al. · Therapeutic Advances in Medical Oncology · 25
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma
2022 · Margherita Rimini, Carles Fabregat-Franco, et al. · Scientific Reports · 24
PDF
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters
2022 · Margherita Rimini, Eleonora Loi, et al. · European Journal of Cancer · 21
PDF
FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study.
2023 · Carlotta Antoniotti, Daniele Rossini, et al. · Journal of Clinical Oncology · 19
PDF
Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer.
2010 · Grazia Artioli, Artioli Grazia, et al. · PubMed · 16
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients
2023 · Margherita Rimini, Carles Fabregat-Franco, et al. · Targeted Oncology · 14
Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy Efficacy
2022 · Gerardo Rosati, Giuseppe Aprile, et al. · Biomedicines · 14
PDF
Rare presentation of endometrial carcinoma with singular bone metastasis
2009 · G. ARTIOLI, M. CASSARO, et al. · European Journal of Cancer Care · 12
PDF
Platinum sensitivity in patients with IDH1/2 mutated vs wild‐type intrahepatic cholangiocarcinoma: A propensity score‐based study
2022 · Monica Niger, Federico Nichetti, et al. · International Journal of Cancer · 11
PDF
Correlation between Magnetic Resonance Imaging and Histopathological Tumor Response after Neoadjuvant Chemotherapy in Breast Cancer
2008 · Maria Ornella Nicoletto, Donato Nitti, et al. · Tumori Journal · 11
Overall survival in BRCA-associated ovarian cancer: case-control study of an Italian series.
2010 · G Artioli, L Borgato, et al. · PubMed · 9
State-of-the-Art of Monoclonal Antibodies for the Treatment of Gastric Cancer
2021 · Debora Basile, Francesca Simionato, et al. · Biologics · 8
PDF
Positive experience of intraperitoneal chemotherapy followed by intravenous chemotherapy in heavily pretreated patients with suboptimal residual ovarian cancer and primary peritoneal cancer.
2010 · Maria Ornella Nicoletto, Maurizia Dalla Palma, et al. · PubMed · 8
Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and Clinical Outcomes in MSI-H population: The PROSECCO Study.
2022 · Floriana Nappo, Antonio Pellino, et al. · Journal of Clinical Oncology · 6
Negative hyperselection and mechanisms of acquired resistance to first-line chemotherapy plus anti-EGFR in patients (pts) with pMMR RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): A translational analysis of the TRIPLETE trial.
2024 · Veronica Conca, Martina Carullo, et al. · Journal of Clinical Oncology · 3
Comparing immunotherapies to other frequently used treatments of gastric cancer
2021 · Debora Basile, Francesca Simionato, et al. · Expert Review of Clinical Pharmacology · 3
FLOaTing toward new standards in locally advanced resectable gastroesophageal cancer
2019 · Lorenzo Fornaro, Caterina Vivaldi, et al. · Journal of Thoracic Disease · 3
PDF
Intraperitoneal Chemotherapy in Patients Pretreated for Ovarian Cancer Matched with Patients Treated with Parenteral Chemotherapy
2016 · MARIA ORNELLA NICOLETTO, ALESSANDRA CASARIN, et al. · Anticancer Research · 3
PDF
Impressive response to denosumab in a patient with bone metastatic adenocarcinoma of the stomach after 2 years of zoledronic acid
2014 · Alessandro Cappetta, Laura Spano, et al. · Anti-Cancer Drugs · 2
108P Negative hyperselection and mechanisms of acquired resistance to first-line chemotherapy plus anti-EGFR in pMMR RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): A translational analysis of the TRIPLETE trial
2024 · V. Conca, M. Carullo, et al. · Annals of Oncology · 1
PDF
Works count: 47
Citation count: 379
H-index: 12
I10-index: 15
Year
Topic
Type